Clinical trial NCT05168748: CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
Official title: Phase I, Open Label, Multicenter, Dose Escalation and Expansion Study of IMJ995 in Acute Lymphoblastic Leukemia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Acute Lymphoblastic Leukemia
Keywords: CAR-T
IMJ995
CD19
CD22
acute lymphoblastic leukemia (ALL)
pediatric
adolescent
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2021-12-23
Enrollment: 0
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous chimeric antigen receptor (CAR) T cells targeting both CD19 and CD22, manufactured with T-Charge(TM) process. CAR-T cells will be investigated as single agent in pediatric and adult acute lymphoblastic leukemia (ALL).

Detailed description: This is a phase I, open label, multicenter, dose escalation and expansion study of IMJ995. The study will investigate single agent IMJ995 in two independent groups of acute lymphoblastic leukemia (ALL) patients:

* Pediatric, adolescent and young adult (AYA) ALL patients up to 29 years old
* Adult ALL patients (≥30 years old) safety cohort The pediatric and AYA ALL group consists of two parts: a dose escalation part to evaluate feasibility, characterize safety and identify the recommended dose (RD) of IMJ995, and a dose expansion part to further characterize safety, cellular kinetics and assess preliminary antitumor activity. Once the RD of IMJ995 is determined for this group, the corresponding expansion part may commence.

Once the RD of IMJ995 is determined for the pediatric and AYA group, a safety cohort for adult ALL patients ≥30 years old may commence in parallel to the above mentioned expansion part.

Eligibility criteria: Inclusion Criteria:

All patients:

* Evidence of CD19 and/or CD22 cell surface expression on B-ALL blasts in bone marrow or peripheral blood by flow cytometry at time of relapse or prior to study entry.

Pediatric, adolescent and young adult ALL patients:

* 1 - 29 years of age at the time of informed consent form (ICF) signature.
* Relapsed or refractory CD19+ and/or CD22+ ALL after 3 or more lines of treatment OR after allogeneic HCT.
* Must have received a CD19-directed CAR-T treatment (with or without blinatumomab), unless prior loss of CD19 cell surface expression occurred or have not been eligible for CD19 directed CAR-T treatment.
* Lansky (age \< 16 years), Karnofsky (age 16-25 years) performance status ≥ 60%. ECOG (age \>25 years) performance status that is either 0 or 1 at screening.

Adult ALL patients aged ≥30 years:

* ≥30 years of age at the time of informed consent form (ICF) signature.
* Refractory or relapsed CD19+ and/or CD22+ ALL including at least one of the following:

  * After allogeneic HCT
  * After 2 or more lines of treatment, including blinatumomab and/or inotuzumab
  * Primary refractory disease (defined as failure to achieve a CR at the end of at least 1 induction chemotherapy)
  * First relapse occurring within 12 months from first remission
* ECOG performance status that is either 0 or 1 at screening.

Exclusion Criteria:

* Allogeneic HCT within 12 weeks prior to screening.
* Presence of isolated extra-medullary disease, testicular involvement or bulky disease
* Patients with concomitant genetic syndromes associated with bone marrow failure states: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome.
* Patients with Burkitt's lymphoma/leukemia
* History of active neurological auto immune or inflammatory disorders

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Incidence and nature of Dose Limiting Toxicities (Dose Escalation part only, in pediatric, adolescent and young adult ALL patients)
timeFrame: 28 days
measure: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (pediatric, adolescent and young adult ALL patients)
timeFrame: 24 months
measure: Number of patients infused with planned target dose
timeFrame: 24 months
Secondary outcomes:
measure: Incidence and nature of DLTs during the first 28 days after IMJ995 infusion (safety cohort for adult ALL).
timeFrame: 28 days
measure: Cellular kinetics of IMJ995 (maximum drug concentration - Cmax)
timeFrame: 24 months
measure: Cellular kinetics of IMJ995 (area under the drug concentration-time curve - AUC)
timeFrame: 24 months
measure: Number of participants with anti-CAR19 and/or anti-CAR22 antibodies
timeFrame: 24 months
measure: Change from baseline in interferon (IFN)-gamma levels in peripheral blood mononuclear cells (PBMCs)
timeFrame: 24 months
measure: Antitumor activity assessed by Complete Remission / Complete Remission with Incomplete Hematologic Recovery (CR/ CRi).
timeFrame: 24 months
measure: Antitumor activity assessed by duration of response.
timeFrame: 24 months
measure: Incidence and severity of AEs and SAEs after IMJ995 infusion (safety cohort for adult ALL).
timeFrame: 24 months
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: